{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:13:13Z","timestamp":1787004793809,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1053\/j.akdh.2024.07.003","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T15:22:04Z","timestamp":1732116124000},"page":"496-503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.1053","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8930-4611","authenticated-orcid":false,"given":"Maria Lourdes Gonzalez","family":"Suarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6206-1111","authenticated-orcid":false,"given":"Silvia","family":"Titan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neera K.","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.akdh.2024.07.003_bib1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ekir.2024.01.046","article-title":"Describing and explaining ADPKD variability within families","volume":"9","author":"Achi","year":"2024","journal-title":"Kidney International Reports"},{"issue":"4","key":"10.1053\/j.akdh.2024.07.003_bib2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/ndt\/gfx327","article-title":"European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants","volume":"33","author":"co-chairs","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1053\/j.akdh.2024.07.003_bib3","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.34067\/KID.0000000000000296","article-title":"Beyond loss of kidney function: patient care in autosomal dominant polycystic kidney disease","volume":"4","author":"Hogan","year":"2023","journal-title":"Kidney360"},{"issue":"1","key":"10.1053\/j.akdh.2024.07.003_bib4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2024.07.003_bib5","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2024.07.003_bib6","doi-asserted-by":"crossref","first-page":"8318","DOI":"10.1038\/s41467-023-43878-9","article-title":"Polygenic risk alters the penetrance of monogenic kidney disease","volume":"14","author":"Khan","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"10.1053\/j.akdh.2024.07.003_bib7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.ajkd.2020.12.020","article-title":"Assessing risk of Rapid progression in autosomal dominant polycystic kidney disease and special Considerations for disease-Modifying therapy","volume":"78","author":"Chebib","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.akdh.2024.07.003_bib8","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/j.ajkd.2017.01.046","article-title":"PKD2-Related autosomal dominant polycystic kidney disease: prevalence, clinical presentation, mutation spectrum, and prognosis","volume":"70","author":"Cornec-Le Gall","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.akdh.2024.07.003_bib9","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","article-title":"Autosomal dominant polycystic kidney disease: core curriculum 2016","volume":"67","author":"Chebib","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.akdh.2024.07.003_bib10","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2215\/CJN.16871020","article-title":"Overweight and obesity and progression of ADPKD","volume":"16","author":"Nowak","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.akdh.2024.07.003_bib15","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A practical guide for treatment of rapidly progressive ADPKD with tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2024.07.003_bib16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.akdh.2024.07.003_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100639","article-title":"Tolvaptan and kidney function decline in older Individuals with autosomal dominant polycystic kidney disease: a pooled analysis of randomized clinical trials and Observational studies","volume":"5","author":"Chebib","year":"2023","journal-title":"Kidney Med"},{"issue":"5","key":"10.1053\/j.akdh.2024.07.003_bib18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ndt\/gfab312","volume":"37","author":"M\u00fcller","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"25","key":"10.1053\/j.akdh.2024.07.003_bib11","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.akdh.2024.07.003_bib12","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.akdh.2024.07.003_bib13","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ekir.2022.02.009","article-title":"Pooled data analysis of the long-Term treatment effects of tolvaptan in ADPKD","volume":"7","author":"Zhou","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"8","key":"10.1053\/j.akdh.2024.07.003_bib14","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/ckj\/sfac076","article-title":"Evaluating the impact of a Risk Evaluation and Mitigation Strategy with tolvaptan to monitor liver safety in patients with autosomal dominant polycystic kidney disease","volume":"15","author":"Estilo","year":"2022","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1053\/j.akdh.2024.07.003_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.akdh.2023.02.002","article-title":"Pharmacologic management of autosomal dominant polycystic kidney disease","volume":"30","author":"Ackley","year":"2023","journal-title":"Adv Kidney Dis Health"},{"issue":"1","key":"10.1053\/j.akdh.2024.07.003_bib20","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2017050483","article-title":"Genetic complexity of autosomal dominant polycystic kidney and liver diseases","volume":"29","author":"Cornec-Le Gall","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2024.07.003_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.akdh.2023.04.004","article-title":"Genetic spectrum of polycystic kidney and liver diseases and the resulting phenotypes","volume":"30","author":"Yang","year":"2023","journal-title":"Adv Kidney Dis Health"},{"issue":"11","key":"10.1053\/j.akdh.2024.07.003_bib22","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1681\/ASN.2019030298","article-title":"ALG9 Mutation Carriers develop kidney and liver cysts","volume":"30","author":"Besse","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2024.07.003_bib23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ajhg.2021.11.016","article-title":"Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype","volume":"109","author":"Senum","year":"2022","journal-title":"Am J Hum Genet"},{"issue":"6","key":"10.1053\/j.akdh.2024.07.003_bib24","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, Encoding the Glucosidase II\u03b1 Subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1053\/j.akdh.2024.07.003_bib25","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.kint.2020.02.022","article-title":"Clinical spectrum, prognosis and estimated prevalence of DNAJB11-kidney disease","volume":"98","author":"Huynh","year":"2020","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2024.07.003_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrgastro.2012.254","article-title":"Diagnosis and management of polycystic liver disease","volume":"10","author":"Gevers","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1053\/j.akdh.2024.07.003_bib27","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2215\/CJN.08660621","article-title":"Volume progression and imaging classification of polycystic liver in early autosomal dominant polycystic kidney disease","volume":"17","author":"Bae","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2024.07.003_bib28","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2024.07.003_bib29","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1053\/j.akdh.2024.07.003_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-032620","article-title":"Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis","volume":"10","author":"Griffiths","year":"2020","journal-title":"BMJ Open"},{"issue":"7","key":"10.1053\/j.akdh.2024.07.003_bib31","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/01.ASN.0000018407.60002.B9","article-title":"Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study","volume":"13","author":"Schrier","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2024.07.003_bib32","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/ki.1992.195","article-title":"Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease","volume":"41","author":"Gabow","year":"1992","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.akdh.2024.07.003_bib33","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/ki.2011.411","article-title":"Analysis of baseline parameters in the HALT polycystic kidney disease trials","volume":"81","author":"Torres","year":"2012","journal-title":"Kidney Int"},{"issue":"24","key":"10.1053\/j.akdh.2024.07.003_bib34","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1053\/j.akdh.2024.07.003_bib35","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa054341","article-title":"Volume progression in polycystic kidney disease","volume":"354","author":"Grantham","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.akdh.2024.07.003_bib36","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.kint.2020.04.053","article-title":"Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease","volume":"98","author":"Kramers","year":"2020","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.akdh.2024.07.003_bib37","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.ekir.2023.07.017","article-title":"Cardiovascular manifestations and management in ADPKD","volume":"8","author":"Sagar","year":"2023","journal-title":"Kidney International Reports"},{"issue":"1","key":"10.1053\/j.akdh.2024.07.003_bib38","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12882-019-1555-z","article-title":"Left ventricular hypertrophy in a contemporary cohort of autosomal dominant polycystic kidney disease patients","volume":"20","author":"Chen","year":"2019","journal-title":"BMC Nephrol"},{"issue":"10","key":"10.1053\/j.akdh.2024.07.003_bib39","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/12.10.2075","article-title":"Ambulatory blood pressure in hypertensive patients with autosomal dominant polycystic kidney disease","volume":"12","author":"Li Kam Wa","year":"1997","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.akdh.2024.07.003_bib40","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1681\/ASN.V121194","article-title":"Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and Unique Aspects","volume":"12","author":"ECDER","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2024.07.003_bib41","doi-asserted-by":"crossref","first-page":"c18","DOI":"10.1159\/000081790","article-title":"Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease","volume":"99","author":"Nutahara","year":"2005","journal-title":"Nephron Clin Pract"},{"issue":"2","key":"10.1053\/j.akdh.2024.07.003_bib42","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1681\/ASN.0000000000000253","article-title":"State of the science and Ethical Considerations for preimplantation genetic testing for monogenic cystic kidney diseases and Ciliopathies","volume":"35","author":"Thompson","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.akdh.2024.07.003_bib43","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2215\/CJN.03550320","article-title":"Preimplantation genetic testing for monogenic kidney disease","volume":"15","author":"Snoek","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.akdh.2024.07.003_bib44","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1159\/000518253","article-title":"Preimplantation genetic testing for kidney disease-related genes: a Laboratory's experience","volume":"52","author":"Chaperon","year":"2021","journal-title":"Am J Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2024.07.003_bib45","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1053\/j.ajkd.2018.01.048","article-title":"Preimplantation genetic diagnosis counseling in autosomal dominant polycystic kidney disease","volume":"72","author":"Murphy","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.akdh.2024.07.003_bib46","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.34067\/KID.0007422020","article-title":"Examining the role of novel CKD therapies for the ADPKD patient","volume":"2","author":"Patel","year":"2021","journal-title":"Kidney360"}],"updated-by":[{"DOI":"10.1053\/j.akdh.2024.11.006","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000}}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924001253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924001253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T20:20:06Z","timestamp":1732998006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813924001253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2949813924001253"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2024.07.003","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autosomal Dominant Polycystic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2024.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the National Kidney Foundation, Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}